Chestnut Hill, MA, United States of America

Karl Dane Wittrup

USPTO Granted Patents = 27 (Patent Applications = 15)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 128(Granted Patents)

Location History:

Menlo Park, CA (US) (2019)
Lebanon, NH (US) (2020 - 2022)
Chestnut Hill, MA (US) (2013 - 2023)
Cambridge, MA (US) (2013 - 2024)
Boston, MA (US) (2020 - 2024)

Company Filing History:

20 out of 8,369

Massachusetts Institute of Technology

patents

3 out of 5,303

Leland Stanford Junior University

Nodus Therapeutics, Inc.

patents

5. 2 out of 649

Ohio State Innovation Foundation

patents

6. 2 out of 559

Memorial Sloan Kettering Cancer Center

patents

7. 1 out of 1,206

Dana-farber-cancer Institute Inc.

patents

8. 1 out of 289

Fred Hutchinson Cancer Center

patents

9. 1 out of 2,882

The General Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12433954 - Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs (2025-10-07),

2. 12433946 - Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof (2025-10-07),

3. 12383589 - Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy (2025-08-12),

4. 12295986 - Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancers (2025-05-13),

5. 12258679 - Polyclonal mixtures of antibodies, and methods of making and using them (2025-03-25),

6. 12227559 - Collagen-localized immunomodulatory molecules and methods thereof (2025-02-18),

7. 11970542 - Bispecific antibodies specific for treating hematological malignancies (2024-04-30),

8. 11858993 - Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof (2024-01-02),

9. 11717548 - Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy (2023-08-08),

10. 11642409 - Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof (2023-05-09),

11. 11485781 - Multiple specificity binders of CXC chemokines (2022-11-01),

12. 11459389 - Monoclonal antibodies that bind human CD161 (2022-10-04),

13. 11448643 - Methods to specifically profile protease activity at lymph nodes (2022-09-20),

14. 11390964 - Polyclonal mixtures of antibodies, and methods of making and using them (2022-07-19),

15. 11235032 - Combination immunotherapy dosing regimen for immune checkpoint blockade (2022-02-01),

Title: The Innovative Contributions of Karl Dane Wittrup

Introduction

Karl Dane Wittrup, based in Chestnut Hill, MA, is a notable inventor recognized for his impactful contributions to the field of immunology and biotechnology. With a remarkable portfolio of 22 patents, Wittrup has established himself as an influential figure in the development of innovative therapeutic solutions.

Latest Patents

Wittrup's latest patents showcase his expertise in creating cutting-edge fusion proteins and bispecific antibodies. One of his recent inventions includes "Collagen-localized immunomodulatory molecules and methods thereof," which encompasses immunomodulatory fusion proteins featuring a collagen-binding domain linked to an immunomodulatory domain. These proteins promise to offer new methods for treating cancer through innovative compositions and therapeutic techniques.

Another significant patent registered by Wittrup is titled "Bispecific antibodies specific for treating hematological malignancies." This disclosure presents advanced pre-targeted radioimmunotherapeutics (PRIT) aimed at addressing various hematological disorders. The patented bispecific antibody compositions are designed to target specific antigens, including CD38, BCMA, Muc1, GPRC5D, and Slam7, before delivering a radioactive ligand. This inventive approach enhances the precision and efficacy of treatment for serious conditions, such as B cell hyperproliferative disorders and solid tumors.

Career Highlights

Throughout his career, Wittrup has worked with esteemed institutions that allow him to push the boundaries of medical research. He has been associated with the Massachusetts Institute of Technology and Leland Stanford Junior University, where he utilized his skills to foster significant advancements in his field. His dedication to research and innovation has led to numerous patents, each contributing to the advancement of science and medicine.

Collaborations

Wittrup's journey in innovation has also been marked by fruitful collaborations with notable colleagues such as Jennifer R. Cochran and Darrell J. Irvine. These partnerships have facilitated the sharing of ideas and technological advancements, leading to breakthroughs in the treatment of diseases through innovative therapeutic methods.

Conclusion

Karl Dane Wittrup exemplifies the spirit of innovation through his groundbreaking work and extensive patent portfolio. His contributions to the fields of immunology and biotechnology have the potential to revolutionize therapeutic strategies for cancer and hematological disorders, reflecting the vital importance of inventors in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.